Critical Survey: Shandong Weigao Medical Polymer (OTCMKTS:SHWGF) and Omeros (NASDAQ:OMER)

Shandong Weigao Medical Polymer (OTCMKTS:SHWGF) and Omeros (NASDAQ:OMER) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Profitability

This table compares Shandong Weigao Medical Polymer and Omeros’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Shandong Weigao Medical Polymer	N/A	N/A	N/A
Omeros	N/A	-72.14%	59.71%

Risk and Volatility

Shandong Weigao Medical Polymer has a beta of -0.05, meaning that its stock price is 105% less volatile than the S&P 500. Comparatively, Omeros has a beta of 2.53, meaning that its stock price is 153% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Shandong Weigao Medical Polymer and Omeros, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shandong Weigao Medical Polymer	0	0	0	0	0.00
Omeros	1	1	2	2	2.83

Omeros has a consensus price target of $40.33, suggesting a potential upside of 251.03%. Given Omeros’ stronger consensus rating and higher possible upside, analysts clearly believe Omeros is more favorable than Shandong Weigao Medical Polymer.

Institutional & Insider Ownership

48.8% of Omeros shares are owned by institutional investors. 12.9% of Omeros shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Shandong Weigao Medical Polymer and Omeros”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shandong Weigao Medical Polymer	$1.82 billion	1.11	$314.90 million	N/A	N/A
Omeros	N/A	N/A	-$3.35 million	($0.50)	-22.98

Shandong Weigao Medical Polymer has higher revenue and earnings than Omeros.

Summary

Omeros beats Shandong Weigao Medical Polymer on 8 of the 11 factors compared between the two stocks.

About Shandong Weigao Medical Polymer

Shandong Weigao Group Medical Polymer Company Limited engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China. It operates through Medical Device Products, Orthopaedic Products, Interventional Products, Pharma Packaging Products, Blood Management Products, and Others segments. The company offers single use medical consumables and materials, including infusion sets, syringes, blood bags and blood component segregators consumable, blood sampling products, prefilled syringes for pre-pack medication and medical needles which mainly include intravenous needles, syringe needles, intravenous catheter needles, blood sampling needles and irregular needles; orthopedic materials and instruments, including trauma products of steel plates and screws, spinal implants, and artificial joints; and blood purification consumables and equipment, including puncture needles, extracorporeal blood circuit for blood purification sets, dialyzers and related consumables. It also provides tumour and blood vessel interventional instruments; flushing syringes; blood collection, irradiation, storage, separation and sterilization products; implantation materials and artificial organs; medical PVC granules, plastic packing bags, and carton boxes; medical polymer materials and products; injection puncture Instruments; medicines; and X-ray based irradiation machines. In addition, it is involved in the finance leasing and factoring business; provision of enterprise management advisory services, logistics and storage, and computer technical services; and sale of electronic products. The company was incorporated in 2000 and is based in Weihai, the People’s Republic of China.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company’s products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.